Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20429324 | 0.81 | PDE10A (0.43) | PDE10AMEN1LMNAKMT2AACHE | |
| SCHEMBL1705948 | 0.80 | ESR1 (0.46) | PDE10AIKBKBJAK2ROCK2JAK1 | |
| SCHEMBL1705752 | 0.77 | PDE10A (0.55) | EGFRPDE10A | |
| SCHEMBL4730778 | 0.76 | KDM4E (0.46) | MEN1LMNAKMT2AF2ADORA3 | |
| SCHEMBL873335 | 0.75 | CYP11B1 (0.47) | PRKCZPDE10AADRA2AKCNH2 | |
| SCHEMBL3060870 | 0.75 | EGFR (0.46) | EGFRPRKCZIMPDH2PDE10AMEN1 | |
| SCHEMBL19383227 | 0.74 | PDE10A (0.48) | PDE10A | |
| SCHEMBL10182816 | 0.73 | PRKCZ (0.46) | PRKCZIKBKBROCK1 | |
| SCHEMBL1705009 | 0.73 | PRKCZ (0.46) | PRKCZIKBKBROCK1 | |
| SCHEMBL1705010 | 0.73 | PRKCZ (0.46) | PRKCZIKBKBROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020056345-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| CN-100356979-C | Integrin expression inhibitors | EISAI CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1243583-B1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | EISAI CO LTD (JP) | 2005-09-28 | — | — | EP | disclosed |
| CN-1217936-C | Heterocyclic compounds having sulfonic acid | EISAI CO LTD (JP) | 2005-09-07 | — | — | CN | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-6787534-B2 | SUBSTITUTED QUINOLINE AND ISOQUINOLINE ANTIANGIOGENIC AGENTS; SULFONYLUREAS | EISAI CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
| CN-1414952-A | Heterocyclic compounds having sulfonic acid | EISAI CO LTD (JP) | 2003-04-30 | — | — | CN | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1243583-A1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | Eisai Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | EGFR 576/4885PRKCZ 4621/4885IMPDH2 4659/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | EGFR 576/4885PRKCZ 4621/4885IMPDH2 4659/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | EGFR 787/4885PRKCZ 4693/4885IMPDH2 4600/4885 |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | SLC5A2, SLC5A1, CBR3 | EGFR 2349/4885PRKCZ 4063/4885IMPDH2 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.